Tag: Stake
-
Glaxo to Hike Stake in Theravance – Zacks.com
Proactive Investors USA & Canada Glaxo to Hike Stake in TheravanceZacks.comThe increased holding by the pharma major reflects its confidence in the Relovair program, under which the companies are looking to replace one of Glaxo's best selling drugs Advair by evaluating treatment options for asthma and chronic obstructive …GlaxoSmithKline Boosts Stake In Theravance To 27%RTT…
-
GlaxoSmithKline Boosts Stake In Theravance To 27% – RTT News
RTT News GlaxoSmithKline Boosts Stake In Theravance To 27%RTT NewsThe move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a …GlaxoSmithKline to Increase Its…
-
GlaxoSmithKline Boosts Stake In Theravance To 27% – NASDAQ
RTT News GlaxoSmithKline Boosts Stake In Theravance To 27%NASDAQThe move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a …GlaxoSmithKline to Increase Its Ownership…
-
GlaxoSmithKline Grows Theravance Stake: Investing in the Pipeline – Seeking Alpha
GlaxoSmithKline Grows Theravance Stake: Investing in the PipelineSeeking AlphaChief among the products of their collaboration to date is Relovair, heir to the throne of Advair, GSK's best-selling medicine for asthma attacks and COPD. …and more » View full post on asthma – Google News